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Abstract: Hepatocellular carcinoma (HCC) is a common, life-threatening complication of 
longstanding infection with the hepatitis C virus (HCV), likely a consequence of the direct 
oncogenic activity of the virus cooperating with liver cell inflammation in transforming  
the liver into a mitogenic and mutagenic environment. The achievement of a sustained 
virological response (SVR) to interferon-based therapies has been shown to benefit the 
course of hepatitis C in terms of reduced rates of liver-related complications and mortality 
from all causes. Interestingly, while achievement of an SVR is associated with a negligible 
risk of developing clinical decompensation over the years, the risk of HCC is not fully 
abrogated following HCV clearance, but it remains the dominant complication in all SVR 
populations. The factors accounting for such a residual risk of HCC in SVR patients are 
not fully understood, yet the persistence of the subverted architecture of the liver, diabetes 
and alcohol abuse are likely culprits. In the end, the risk of developing an HCC in SVR 
patients is attenuated by 75% compared to non-responders or untreated patients, whereas 
responders who develop an HCC may be stratified in different categories of HCC risk by a 
score based on the same demographic and liver disease-based variables, such as those that 
predict liver cancer in viremic patients. All in all, this prevents full understanding of those 
factors that drive HCC risk once HCV has been eradicated. Here, we critically review 
current understanding of HCC in SVR patients focusing on factors that predict residual risk 
of HCC among these patients and providing a glimpse of the expected benefits of new  
anti-HCV regimens based on direct antiviral agents. 
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1. Introduction 
Chronic infection with the hepatitis C virus (HCV) is a leading cause of liver-related mortality 
worldwide, since it is a major risk factor for the development of cirrhosis and hepatocellular carcinoma 
(HCC) [1]. Antiviral therapy with interferon (IFN) has long been the only available option to modify 
the course of the infection, since in many patients with a sustained virological response (SVR), it 
succeeded in preventing the onset of life-threatening end-stage complications of hepatitis C [2–7]. 
With all of the caveats related to the retrospective design and inherent selection biases, IFN studies 
associated achievement of an SVR with a 75% reduction of the incidence of HCC in patients who were 
treated at various histological stages of infection [8]. Owing to the residual risk of HCC, which has 
been estimated to be around 0.5%–1% per year, cirrhotic patients successfully achieving an SVR are 
recommended to continue surveillance with abdominal ultrasound (US) in order to detect HCC early 
and improve treatment outcome [9]. In the face of the residual incidence of such a life-threatening 
complication of HCV as HCC, a few studies have only searched for factors responsible for the 
increased risk of this tumor in SVR patients. With the advent of user-friendly, highly effective and safe 
IFN-free therapies based on the combination of direct antiviral agents (DAA), a greater impact of 
antiviral therapy on the prevention of HCV-related complications is awaited, particularly in patients 
with advanced cirrhosis and those with decompensated liver disease who are unfit for IFN therapy, 
while they are at increased risk of HCC development. 
Here, we review the oncogenic mechanisms of HCV and how HCC risk is modified by successful 
anti-HCV therapy, focusing on the role of fibrosis regression and risk factors for HCC. 
2. HCC in HCV-Infected Patients 
HCC is an inflammatory-type neoplasia, which results from the interaction between direct 
carcinogenic effects of HCV proteins, which deregulate host cell cycle check points, and the immune and 
virus-mediated oxidative stress, causing DNA mutations in both infected and uninfected liver cells [10]. 
From a clinical point of view, neoplastic transformation of uninfected liver cells under the pressure of 
inflammatory stimuli released by HCV-infected hepatocytes is of strategic importance in the 
understanding of HCC, which develops years after treatment-induced eradication of infection, as well 
as of tumors recurring in SVR patients years after a successful ablation of an HCC. While advanced 
fibrosis stands as a relevant determinant of HCC risk in both HCV viremic and SVR patients, patient 
age, alcohol abuse and insulin resistance appear to be associated with an increased risk of HCC in both 
patients categories, supporting a multifactorial origin of this neoplasia. Despite initially promising 
results, more than one study investigating genetic predisposition to liver cancer failed to identify any 
robust predictor of HCC development in HCV patients that can be used in clinical practice to optimize 
the management of patients with a liver cancer. More recently, the PNPLA3 polymorphism rs738409 
has been identified to exert a marked influence on hepatocarcinogenesis in patients with cirrhosis of 
European descent; however, these data need further validation. In fact, most publications suffer from 
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major methodological drawbacks because of their case-control, retrospective and single-center design, 
mainly involving selected Asian populations. Prospective cohort studies conducted in large 
homogeneous populations with a sufficient number of events during follow-up require a long time to 
be conducted and, therefore, are still scarce [11]. 
3. The Clinical Benefits of an SVR to Interferon 
In patients with advanced liver fibrosis due to HCV, achievement of an SVR has been associated 
with a significant reduction of such life-threatening complications as liver failure and HCC [2–7]. 
Owing to the fact that clinical decompensation rarely occurs in SVR patients, HCC stands as the 
commoner complication in patients who are successfully treated with IFN-based regimens, with a 
reported incidence of less than 1% [2–7,12,13] (Table 1). While the persistence of HCC in SVR 
patients might well reflect the pro-carcinogenic effects of residual cirrhosis, alternatively, data suggest 
a pathogenetic role of non-virus-related carcinogenic factors, like diabetes and alcohol, as well as the 
confounding effect of time required for newly-developing HCC to become clinically apparent [14]. 
Clinical benefits following HCV eradication were first reported in a retrospective analysis of 329 
compensated cirrhotics in Europe, who were followed-up for 45 (6–93) months after the end of IFN 
therapy [15]. That study reported no events among 14 responders, compared to a five-year estimated risk  
of 2.1% of HCC and 7% of decompensation in untreated patients, respectively. These preliminary 
observations were confirmed and strengthened by a study in Japan, which added evidence of improved 
survival in SVR patients where HCC, which was detected in less SVR patients (27/836) than in  
non-responders (214/1556) or untreated (67/395) cirrhotics, was the dominant cause of liver-related 
mortality in patients not achieving an SVR (66%) [2]. These were also the findings of a retrospective 
multicenter study in Italy involving 1214 patients with cirrhosis and 124 SVR patients who were 
followed for 96 (6–167) months [4]. In that study, HCC was the only complication occurring among 
patients with an SVR (SVR vs. non-SVR, 5.6% vs. 16%, p < 0.001), whereas no other liver-related 
events were registered. Although not linear, the yearly incidence rate of HCC in SVR cirrhotics was 
lower than in non-responders (0.66 vs. 2.10), the latter ones having a 2.59-fold higher risk of 
developing an HCC. While older age (>54 years), male gender, low platelet count and absence of SVR 
were independently associated with an increased risk of developing liver cancer, liver-related mortality 
was higher in non-SVR than in SVR patients (RR 7.59 (1.84–31.29), p < 0.01), all-cause mortality 
rates, however, remaining unaffected [4]. Likewise, Veldt and colleagues [5] reported lower HCC rates 
among 142 SVR patients with a histological pre-treatment diagnosis of advanced fibrosis (Ishak score 
S4–S6), which however did not exceed the rates reported in non-responders at five years (p = 0.192). 
Moreover, in that study, HCC developed between 1.7 and 3.9 years from treatment failure, with an 
incidence of 1.8% at one year and 9.2% at five years, i.e., at higher rates than those observed in the Italian 
study. This was also the message of the scrutiny of 307 HCV patients with advanced liver disease in France 
who, after being treated with IFN-based therapies, were regularly followed-up for 3.5 (1–18) years [16]. 
HCC developed in six out of the 103 patients with an SVR (5.8%), with an estimated yearly incidence rate 
of 1.24 (95% C.I. 0.28–2.20), which was lower than the rates observed among non-responders (20%), 
with an annual incidence rate of 5.85 (95% C.I. 4.23–7.47). In this study, too, treatment failure was an 
independent predictor of HCC risk, together with older age (>60 years) and such markers of hepatitis 
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severity as high bilirubin values, low platelet count and low serum albumin. The existence of a 
relationship between treatment failure and HCC risk in patients with advanced HCV emerged also in a 
multinational study of 530 patients who were followed-up for a median of 8.4 (6.4–11.4) years after 
treatment completion: an SVR was achieved by 192 (36%), seven of whom (4%) developed HCC 
during seven years from treatment completion, i.e., at a lower rate than that reported in non-SVR 
patients (18%) [7]. Despite intense scrutiny of the databases, all of these studies failed to identify 
predictors of increased HCC risk in SVR patients other than those predicting HCC in viremic patients. 
All in all, these retrospective studies validated the findings of the only prospective investigation with 
IFN that was carried out in Japan in 271 patients who were followed-up for seven years after treatment 
completion [17]. In that cohort, the rates of HCC and liver-related death were lower in SVR patients 
than in non-responders (11/64 vs. 73/207, 17% vs. 35%, p = 0.008 and 0/64 vs. 32/207, 0% vs. 15%,  
p = 0.0002), whereas rates of HCC were also lower in SVR patients when compared to untreated 
patients (age-adjusted hazard ratio 0.31 (95% C.I., 0.16–0.61), p < 0.001). Importantly, none of the 
SVR patients died of liver cancer. It should be mentioned, however, that assessment of clinical benefits 
provided by an SVR to IFN may be biased by methodological flaws in the design and conduct of 
studies that were originally designed to evaluate the antiviral activity of IFN, not its anticancer 
properties. In those studies, in fact, patient enrollment was skewed toward highly-selected individuals 
who were fit to IFN therapies, thereby excluding a majority of patients with more advanced liver 
disease who were IFN unable or intolerant, while notoriously being at high risk of developing HCC. 
Further, none of these studies had patients stratified pretreatment for relevant predictors of HCC risk, 
like age, hepatitis severity, alpha-fetoprotein (AFP) levels and co-morbidities, therefore making a 
comparison of the outcomes between treated and untreated patients difficult. Finally, the length of and 
adherence to follow-up between treated and untreated patients was substantially heterogeneous, a fact 
that, together with the lack of a predefined strategy of HCC surveillance, led to inaccurate estimates of 
HCC rates in most studies. 
4. Expected Benefits of All Oral Anti-HCV Therapy 
All oral therapy of hepatitis C is expected to provide additional clinical benefits with respect to 
IFN-based regimens [18]. Second wave direct antiviral agents, in fact, are virtually applicable to all 
patients with HCV, independently of the status of clinical compensation and the presence of 
comorbidities, and are safe and highly effective against all genotypes of HCV, while being generally 
well tolerated. Combination therapies based on an NS5A inhibitor associated with other classes of 
DAA guarantee more than 95% SVR rates in patients with chronic hepatitis C due to the difficult to 
cure genotype 1 and more than 90% rates in those with compensated cirrhosis, increasing by 2.6-fold 
the success rate of antiviral therapy in terms of intention to treat analysis compared to IFN-based 
regimens [19,20]. Importantly, oral regimens were highly effective and safe in patients with 
decompensated cirrhosis who are interferon unable, a fact that expand the spectrum of clinical benefits 
of antiviral therapy in the hepatitis C scenario [19–21]. While an SVR in patients with cirrhosis is 
definitely associated with high rates of liver function improvement in terms of both MELD and Child 
Pugh scores, what is still unclear is whether the risk of developing a liver cancer in patients treated 
with oral regimens is attenuated compared to what has been seen in patients treated with IFN. 
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Translating our experience to patients with chronic hepatitis B, in whom the introduction of highly 
effective and safe NUC analogs to treat HBV expanded survival expectancy favoring the onset of liver 
cancer in survivors [22,23], one wonders whether a similar scenario can be foreseen in HCV. A 
preliminary report in 120 patients with advanced cirrhosis who received a 12-week course of 
Sofosbuvir (a nucleotide inhibitor of NS5B) + Simeprevir (a NS3-4A protease inhibitor) provided an 
overall rate of 81% SVR, but left a substantial number of patients at risk of developing HCC in the  
12 months post-treatment. 
Table 1. Estimated annual incidence and associated risk factors of hepatocellular 
carcinoma (HCC) in HCV patients with cirrhosis or advanced fibrosis stratified by 
treatment response. SVR, sustained virological response. 
Reference No. of Patients 
Follow-up Months 
(range) 
HCC Risk Factors 
HCC Incidence 
SVR + SVR − 
Yoshida et al.,  
2004 [2]  
2392 (7) 45 (6–93) 
** Advanced 
fibrosis;  
age > 60 male sex 
0.4% 1.7% 
Shiratori et al.,  
2005 [17] 
271 (7) 100.8 (76.8–136.8) 
Age >60  
albumin < 4 mg/dL 
2.4% 5% 
Bruno et al.,  
2007 [4] 
920 (8) 96 (6–169) 
Cirrhosis; age > 54  
Male sex;  
platelets < 109,000 
0.7% 2% 
Cardoso et al.,  
2010 [16] 
307 (18) 42 (12–216) 
Cirrhosis; bilirubin 
> 0.9 mg/dL  
albumin < 4 g/dL  
platelets < 150,000 
0.3% 1.1% 
Yu et al., 2006 [3] 1619 (16) 70 (12–180) Genotype 1; age  0.76% 2.2% 
Veldt et al., 2007 [5] 479 (4.9) 25.2 (9.6–58.8) No features found 0.4% 1.9% 
Van der Meer,  
2012 [7] 
530 (11.4) 100 (77–144)  
Male sex; age > 49 
diabetes genotype 3; 
alcohol abuse 
0.3% 1.6% 
Mallet et al.,  
2008 [6] 






Fattovich et al., 
1997 [15] 
329 (12.7) 60 
Bilirubin > 1 mg/dL 
age > 57 
1% 2.3% 
* SVR patients; ** non-SVR and untreated patients. 
5. Indicators of HCC Risk in SVR Patients 
Owing to the low incidence of HCC among SVR patients, the study of factors associated with liver 
cancer development in this population is rather problematic. So far, no single clinical or histological 
predictor of HCC development has been identified in SVR patients, reinforcing therefore the concept 
that HCC risk in HCV patients may be multifactorial [2–6,17]. 
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5.1. Host-Related Predictors 
In 2012, Chang and colleagues developed a predictive score (ScoreHCC) for HCC development in 
patients with an SVR following the scrutiny of more than 800 SVR patients who were followed-up for 
41.3 (3.5–113.9) months after anti-HCV treatment completion.(22) As older age (>65 years), advanced 
fibrosis (F3–F4), lower platelets count (<150,000/mm3) and high AFP levels (≥20 ng/mL) were  
found to be independent risk factors for HCC, a predictive model was constructed attributing points to 
these variables, which allowed stratification of patients into three risk groups for HCC: low risk  
(ScoreHCC ≤ 10 points), intermediate risk (ScoreHCC 11–15) and high risk (ScoreHCC ≥ 16). The risk of 
HCC, in fact, progressively increased across groups from 1.37%–9.14% and 30.77% (p < 0.001), but 
among the 37 SVR patients who developed HCC during a median follow-up of four years, more than 
half were in the low-risk category, whereas, as expected, the incidence of HCC gradually increased 
over post-treatment follow up. While all of these findings stress the importance of time factors in HCC 
development, they actually work against the application of this propensity score with the aim of 
optimizing screening strategies in the hyperendemic areas of hepatitis, mainly owing to the many 
patients in the lower bound of risk who in the end developed a liver cancer. The study was also far 
from being accurate in the search of HCC predictors, as it failed to provide information on the 
potential role of such relevant exogenous cofactors as alcohol and BMI that potentially might have 
tuned the residual risk of liver cancer in many patients [24]. This notwithstanding, if validated, this 
HCC score algorithm might be considered for improving the design of studies of HCC prevention, 
whereas it does not fit the safety criteria for refining strategies of surveillance in terms of cost 
effectiveness. This algorithm has not been validated in the West: in a multinational study in the U.S., 
Canada and Europe, age at the time of antiviral treatment emerged as the only variable associated with 
an increased risk of HCC [25]. Though rates of HCC were 2.6% for patients <45 years, 9.3% for 
patients 45–60 years and 12.2% for patients >60 years (p = 0.006), the study missed data on potential 
confounders, like the interaction of age with disease severity, diabetes and alcohol. More recently,  
in a cohort of 642 SVR Asian patients (13% cirrhotics), HCC was strongly associated with cirrhosis  
(HR 4.98 (95% C.I. 2.32–10.71), p < 0.001) and less strongly with age (HR 1.06 (95% C.I. 1.02–1.11),  
p = 0.005) and γGT (HR 1.01 (95% C.I. 1.00–1.013), p < 0.001) [26]. Whilst no HCC-associated factors 
were found among SVR cirrhotics, in non-cirrhotic SVR patients, high baseline γGT (HR 6.44  
(95% C.I. 2.20–18.89), p = 0.001) and age >60 years (HR 3.68 (95% C.I. 1.33–10.17), p = 0.012) were 
associated with an increased risk of HCC. Interestingly, following stratification of non-cirrhotic SVR 
patients into three categories at different HCC risk, compared to patients without any risk factor, the 
HR of HCC was 9.06 (C.I. 2.1–40.9, p = 0.004) in patients with one risk factor and 20.62 (C.I.  
3.8–112.8, p < 0.001) in patients with two risk factors, corresponding to a yearly HCC incidence of 
0.14% vs. 1.22% vs. 4.54% [26]. 
5.2. Residual Liver Fibrosis as a Risk Factor of HCC 
A study in France first demonstrated that achievement of an SVR was not enough to prevent 
cirrhosis-related complications in patients in whom liver fibrosis had not regressed [6]. In that study, 
96 HCV patients with a pre-treatment histological diagnosis of cirrhosis, who were treated with IFN-based 
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regimens and followed-up to 118 months after treatment completion, underwent a post-treatment liver 
biopsy, independently of the treatment outcome, after a median period of 17 months from the end of 
antiviral therapy. While cirrhosis regression was demonstrated in 18 (19%) patients, 17 with an SVR, 
liver-related complications occurred less frequently among SVR than among non-responders (10%  
vs. 40%, 11% vs. 38%, p = 0.009). HCC was the commonest complication occurring in three (8.6%) 
SVR patients vs. 14 (23%) non-responders, whereas all but one SVR patients remained free from 
decompensation throughout the follow-up period. Interestingly, none of the patients in whom cirrhosis 
regresses at post-SVR liver biopsy showed any complication, whereas clinical events occurred only 
among those who were persistently cirrhotic at follow-up biopsy. Among patients with cirrhosis 
regression, one non-liver-related death was recorded, only. In a study in Italy, regression of cirrhosis 
was demonstrated in 60% of patients who were examined with a percutaneous liver biopsy performed 
five years after achieving an SVR, on average [27]. 
5.3. Direct Mechanisms of HCV Carcinogenicity 
Occult infection with HCV has long been questioned to explain both hepatic and extrahepatic 
complications in HCV patients, yet qPCR investigations in various tissues have conclusively 
demonstrated this hypothesis to be unlikely [28]. Instead, data point to a direct effect of the virus in 
infected cells that may take place long before treatment-related eradication of the infection, thereby 
explaining cases of HCC developing years after the curing of hepatitis with IFN. The virus infection 
results in deregulation of host cell-cycle checkpoints, immune and host-mediated oxidative stress and 
DNA damage, which may in fact lead to the accumulation of mutations of host DNA, eventually 
resulting in malignant transformation of infected cells that may require a lengthy time to become 
clinically evident [10]. The non-structural protein 5B (NS5B)-mediated loss of retinoblastoma protein 
(Rb) expression likely renders infected hepatocytes unable to mount a normal response to DNA 
damage and can be expected to promote genomic instability and increase the risk of HCC, while the 
apparent preservation of miR-122 expression in HCV-associated HCC, despite its loss in HCC due to 
other etiologies, may account for cancer development within HCV-infected hepatocytes. On the other 
hand, cells maintaining miR-122 expression would be at risk for persisting direct effects of HCV, 
being selected during progression toward cancer [10]. 
5.4. Exogenous Risk Factors  
It is well established that many cases of HCC develop in the context of non-virological, 
environmental risk factors, including alcohol abuse and tobacco smoking [29,30], which may play a 
role in the residual risk. 
Oxidative stress may also be a driving mechanism in HCC developing in alcohol abusers, though a 
HCC risk threshold for ethanol consumption has not been identified: daily intake of ≥80 g of ethanol 
for >10 years is thought to increase the risk of HCC by approximately five-fold, women being more 
vulnerable to alcohol toxicity than men [31–35]. This was the clear message of one study in U.K. 
where 1.3 million women were involved in breast cancer screening programs, where minor amounts of 
alcohol consumption, like 10 g/day on average, were associated with a significant increase of HCC risk 
compared to the general population (increase of RR 24% (95% C.I. 2–51), p = 0.03) [35]. Hepatic 
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metabolism of ethanol might lead to increased conversion in the liver of pro-carcinogens into active 
carcinogens, whereas acetaldehyde and oxygen-free radicals generated by ethanol metabolism may 
directly harm liver cells by initiating peroxidation of membrane lipids [34]. All in all, oxidative stress 
is the leading mechanism that transforms the liver in a mitogenic and mutagenic environment [36]. In 
HCV-infected patients, alcohol may synergically lead to an acceleration of fibrosis deposition and 
progression to cirrhosis and liver-related complications [37]. The fibrogenetic process induced by 
alcohol may be accelerated also in patients after clearance of HCV, since residual fibrosis from viral 
hepatitis may potentially enhance ethanol’s effects. Not surprisingly, therefore, alcohol intake has been 
associated with HCC development in patients who achieved an SVR to IFN-based therapies, as well. 
This is the message of a study of 792 SVR patients (1.8% cirrhotics), who were followed-up for  
62 months, where at multivariate analysis, alcohol consumption emerged as an independent predictor 
of HCC (≥50 vs. <50 g/day: RR 3.86 (1.58–9.44)), together with F3/F4 fibrosis (RR 5.37 (2.27–12.75)) 
and older age (3.99 (1.71–9.28)) [38]. Similar results come from another study in Japan, where HCC 
risk was higher in patients with an alcohol intake ≥27 g/day when compared to non-drinkers  
(p = 0.015), whilst no differences were observed when the threshold of alcohol consumption was 
raised to ≥80 vs. <80 g/day (p = 0.447) [39]. More recently, in a cohort of 4302 HCV Japanese patients 
treated with IFN who were followed up for 8.1 years, a cumulative alcohol intake >200 kg (p < 0.05) 
was also associated with increased risk of HCC following an SVR [40]. 
There is convincing evidence that both obesity and diabetes may enhance the risk of HCC, 
independently of a successful antiviral treatment. The importance of diabetes has been confirmed in a 
recent SEER (surveillance epidemiology and end results)-based re-analysis, showing an up to  
three-fold increase in the risk of HCC, regardless of the presence of other major risk factors [41]. 
Further evidence that obesity and diabetes are either jointly or independently associated with an 
increased risk of HCC is provided by an Italian case-control study and by several large-scale 
epidemiological studies that have associated the overweight and obesity pandemic in the general 
population with an increased risk of HCC [42,43]. In a cohort of 900,000 American adults, the risk of 
dying from liver cancer was in fact 4.5-times higher in men with a BMI ≥ 35 kg/m2, compared to men 
with a normal BMI (18.5 to 24.9 kg/m2) [29]. In a prospective observational study in Taiwan, extreme 
obesity (i.e., body mass index > 30 kg/m2) was independently associated with a four-fold risk of HCC 
(RR 4.13 (95% C.I. 1.38–12.4)) among anti-HCV positive subjects and a two-fold risk (RR 2.36  
(95% C.I. 0.91–6.17)) in those who tested seronegative, thus confirming its potential role in promoting 
HCC development in SVR patients (RR 1.36 (95% C.I. 0.64–2.89)) [44] These and other studies 
contributed to the increased recognition of nonalcoholiceatohepatitis (NASH) being a significant  
cause of both cirrhosis and HCC, with many patients, however, progressing to liver cancer without 
histological evidence of advanced fibrosis or cirrhosis [45]. Recently, Dyson and colleagues found  
that nonalcoholic fatty liver disease (NAFLD) accounted for one third of all cases of HCC seen in  
a referral center in the U.K., whilst in the same period, metabolic risk factors, like hypertension, 
hypertriglyceridemia, reduced HDL cholesterol and previous cardiovascular events, were present in 
66.1% of the patients with a new diagnosis of HCC, irrespective of liver disease etiology [46]. In the 
last 10 years, evidence has accumulated that HCC in histologically-proven NAFLD often arises 
without cirrhosis, suggesting that non-cirrhotic HCC may occur more commonly in NAFLD than in 
liver diseases of other etiologies, whereas HCC has also been reported in patients with metabolic 
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syndrome lacking any histological feature of steatohepatitis and fibrosis [31,47]. The precise 
mechanisms through which metabolic factors drive HCC development are complex and beyond the 
purpose of this article; however, major systemic and liver-specific molecular mechanisms, like insulin 
resistance, hyperinsulinemia, increased expression of tumor necrosis factor signaling pathways and 
direct lipotoxicity, are major players in the development of HCC [31,47]. 
Diabetes has long been recognized as a predictor of HCC in patients with chronic hepatitis C  
(p = 0.005), HCC rates decreasing in patients with a mean hemoglobin A1c (HbA1c) level <7.0% 
during follow-up with respect to patients with an unbalanced diabetes (hazard ratio, 0.56, 95% 
confidence interval, 0.33–0.89, p = 0.015) [40]. 
Hepatic steatosis after SVR behaves differently from that in NASH, suggesting the possibility that 
steatosis and HCV infection may cooperate in the development of HCC. In one study, moderate 
steatosis was an independent risk factor for HCC among 266 patients 10 (±4) years after achieving  
a SVR, as it occurred in seven (2.6%) patients, only [48]. While pre-treatment histological steatosis  
(G2-3) emerged as an independent risk factor for HCC (p = 0.0002) together with fibrosis stage  
(F3–F4, p = 0.0028) and older age (≥55 years), it declined at the time of HCC diagnosis compared to 
baseline histological assessment (G0 in one, G1 in three and G2 in one), and interestingly, none of the 
patients with G0 steatosis at baseline developed an HCC [48]. 
5.5. Tobacco Smoking 
While tobacco smoke contains more than one hundred potential carcinogens that may affect the 
liver, it is still unclear whether tobacco smoking is causally associated with liver cancer [49,50]. A 
meta-analysis on the effect of smoking on liver cancer [51] reported an overall OR of 1.56  
(95% C.I. 1.29–1.87) by comparing current smokers to never smokers and of 1.49 (95% C.I. 1.06–2.10) 
comparing former smokers to never smokers. The associations among current smokers appeared to be 
consistent with the overall RR regardless of region, study design, study sample size and publication 
period. Instead, the synergistic interaction between tobacco smoking and viral hepatitis are 
inconsistent: a study in Taiwan found a higher RR of tobacco smoking among HBV-negative than 
among HBV-positive subjects [52], whereas a study in Japan found a higher RR among HBV-positive 
subjects only [53]. More convincing is the evidence that tobacco smoking is a cofactor for the 
development of liver cancer in patients with established cirrhosis. These are the conclusions of a 
retrospective study in China, assessing the smoking habits of 36,000 adults who had died from liver 
cancer and 17,000 who had died from cirrhosis, showing that among men with chronic HBV infection, 
HCC risk was 33% in smokers and 25% in nonsmokers [54]. While the RR was independent of age, it 
was similar in urban and rural areas, was not significantly related to the age when smoking started, but 
was significantly (p < 0.001) greater for cigarette smokers than for smokers of other types of tobacco, 
with a greater hazard ratio among those who smoked 20/day (for men RR 1.50, 95% C.I. 1.39–1.62, 
for women RR 1.17, 95% C.I. 1.06–1.29) than among those who smoked fewer cigarettes [54]. Finally, 
the association between tobacco smoking and HCC risk was also investigated through a case-control 
study in Italy. Current smoking was unrelated to HCC risk among uninfected individuals (OR 1.0;  
95% C.I. 0.5–2.0), but it seemed to enhance the adverse effect of hepatitis viruses among HBsAg+ or 
anti-HCV+ individuals, with an OR of 23.4 among never or former smokers (at least 12 months) vs. 
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44.3 among current smokers (at least one cigarette/day for at least one year) [55]. The role of tobacco 
as a cause of residual HCC risk in SVR patients has never been evaluated. 
6. Conclusions 
There is overwhelming evidence that HCV patients who achieve an SVR to interferon-based 
therapies have a significantly reduced risk of developing a liver cancer in the short/medium term. 
Additional studies are therefore required to establish whether prevention of HCC in SVR patients is 
maintained lifelong. The puzzling question of why one quarter of patients who successfully responded 
to IFN therapy did develop a liver cancer during follow-up remains elusive. HCC risk in fact may be 
multifactorial, as suggested by its association with patient age and liver disease severity at treatment 
onset, post-treatment persistence of excessive fibrosis in the liver, coexistence of diabetes, being 
overweight and alcohol abuse. A worrisome aspect of these findings is the increased HCC risk in older 
patients and in those with more advanced liver disease, suggesting that long standing infection with 
this potentially carcinogenetic virus is a primary pathogenetic factor for liver cancer during chronic 
infection with HCV. This questions current strategies of prioritization of all oral therapy in patients 
with advanced hepatitis C, which are in place in most European and U.S. States, whereas a refinement 
of our current policies of HCV therapy worldwide should be pursued. Our strategies against HCC in 
HCV patients need to be implemented following the finding that metabolic syndrome and alcohol 
abuse are involved in residual HCC risk in SVR patients. Studies are deemed necessary to establish 
whether treatment of comorbidities may further contribute to prevention of HCC in HCV patients 
undergoing successful eradication of the infection. 
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